High inter-individual variability in tacrolimus clearance is attributed to genetic
polymorphisms of CYP3A enzymes. However, due to CYP3A phenoconversion induced by …

Tacrolimus is a first-line calcineurin inhibitor (CNI) and an integral part of the
immunosuppressive strategy in solid organ transplantation. Being a dose-critical drug …

This study evaluated the effects of cytochrome P450 (CYP) 2C19 polymorphisms on
tacrolimus pharmacokinetics when coadministered with voriconazole. Eighteen healthy …

Aim In a cohort of 298 de-novo renal recipients treated with a standard tacrolimus loading
dose of 0.2 mg/kg, the combined effects of the CYP3A5* 1, POR* 28, and CYP3A4* 22 …

Study Objective To determine the effect of tacrolimus trough concentrations on clinical
outcomes in kidney transplantation, while assessing if African‐American (AA) race modifies …

Immunosuppression management after lung transplantation continues to evolve, with an
increasing number of agents available for use in various combinations allowing for more …

Introduction: De novo donor-specific antibodies (dn DSA) directed against HLA are a major
contributing factor to the chronic deterioration of renal allograft function. Several factors …

There is significant variability in the serum concentrations of tacrolimus attained early post
transplant due to drug interactions and genomic variation. We evaluated whether tacrolimus …

Neural stem cell (NSC) transplantation has been reported to be a leading strategy to
stimulate neuroplasticity, repair neuronal loss and promote the morphologic and functional …

Background: After heart transplantation (HTx), the interindividual pharmacokinetic variability
of immunosuppressive drugs represents a major therapeutic challenge due to the narrow …